1. Cancer Discov. 2018 Nov 21. doi: 10.1158/2159-8290.CD-NB2018-155.

[Epub ahead of

print]

Anti-CD47 Agent Boosts Macrophage Activity in NHL.

[No authors listed]

The anti-CD47 drug Hu5F9-G4, also known as 5F9, in combination with the anti-CD20
therapy rituximab, may be a promising treatment for some forms of non-Hodgkin
lymphoma because it allows macrophages to recognize and attack cancer cells. In a
phase Ib trial testing the combination, patients with relapsed/refractory diffuse
large B-cell lymphoma or follicular lymphoma had an objective response rate of
50% and few side effects.

©2018 American Association for Cancer Research.

DOI: 10.1158/2159-8290.CD-NB2018-155
PMID: 30464001